Editor's key points † This is a review of literature on IgE-mediated allergy to local anaesthetics. † The incidence of IgE-mediated allergy was ,1%, based on 2978 referrals reported in 23 case series. † This review will assist the allergy clinics to design their services, triage referrals, and manage resources.
time-consuming and do not offer clear guidance on selection of patients for investigation. 8 -13 Given the rarity of true IgE-mediated reactions to LA and the existing pressures on allergy services within the UK, we have critically reviewed the literature on IgE-mediated allergy to these agents, with a view to ensuring that drug allergy clinics are able to triage referrals and direct their resources at those patients with a history suggestive of IgE-mediated allergy.
Methods and data sources
A MEDLINE search of the English language literature was carried out to identify clinical studies and case reports describing true allergy to LAs. The key search terms used were 'local anaesthetics', 'allergy', and 'true allergy'. The main periods of review were 1990 -2011, 1975-1990, and 1950 -1975 . The types of publications reviewed included large controlled and uncontrolled prospective and retrospective studies, individual case reports, and relevant correspondence. In addition, relevant references were also obtained by scrutinizing the bibliography accompanying chapters on LA allergy from a reputable textbook of allergy. 14 The review of literature was restricted to type 1 or IgE-mediated immediate hypersensitivity and the articles referring to delayed type hypersensitivity were excluded from consideration ( Fig. 1 ).
In addition, drug analysis print (DAP) data derived from the UK yellow card reporting scheme for lidocaine, bupivacaine, tetracaine, articaine, levobupivacaine, procaine, ropivacaine, prilocaine, and benzocaine were obtained from the Medicines and Healthcare Products Regulatory Agency 
Results
Twenty-three case series involving 2978 patients with suspected LA allergy and 31 individual case reports were identified that described evaluation and testing for true allergy to LAs. These have been summarized in Table 1 (large case series) and Supplementary Table S1 (individual case reports), respectively. Individual case reports were not included in the calculations for the incidence of true allergy. Similarly, data from the UK yellow card reporting system (DAP data: Supplementary Table S2) , briefly discussed below, was excluded from the calculations.
Case series
True IgE-mediated allergy to an LA agent was proven in 29 patients out of a total of 2978 patients screened in the larger series. This makes the reported prevalence of LA allergy in the literature ,1% (0.97%).
In 75% (22/29) of these cases, this was clearly documented to an amide agent ( Table 2 ). The predominance of amide agents as allergenic triggers in contrast to esters probably reflects the current practice of preferential use of amide agents for local anaesthesia. although some have preferred to use dilutions. 13 17 Intra-dermal tests Intra-dermal tests have been used variably, either with or instead of SPTs in the initial investigation of these patients. Of 2978 patients, 2648 (89%) had intra-dermal testing. Thirty-seven of these were positive (1.4%) when using 1:10 or greater dilutions of LA. Neat preparations of LA were not commonly used for intra-dermal testing.
Individual case reports

Subcutaneous challenge
Of the total 2978 patients, 2560 patients (86%) investigated for LA allergy in the case series had subcutaneous challenges. Positive challenge tests were reported in 19 patients (0.74%). In most cases, this procedure has been used to demonstrate tolerance to an alternative agent rather than confirm allergy.
DAP data
Data from the MHRA regarding reports of possible immunemediated reactions to lidocaine, bupivacaine, tetracaine, articaine, levobupivacaine, procaine, ropivacaine, prilocaine, and benzocaine are shown in Supplementary Table S2 . The yellow card reporting system that is used to collect these data allows registration of all suspected cases of adverse reactions after LA administration. These data are not clearly designed to differentiate between different types of reactions or demonstrate that the aetiology of these cases was proven by investigations. We have therefore not used these data for the purpose of calculations.
Discussion
True IgE-mediated allergy to LAs is rare and previously reported to be ,1%. 4 -6 In this review, the analysis of published series and large studies of suspected cases of LA allergy in the English literature between 1952 and 2011 has confirmed this finding. The calculated incidence of reported cases of true IgE-mediated allergy to LA was found to be 0.97%. Individual case reports describing patients with documented and proven allergy to LA preparations were noted and recorded separately, but not included in the calculation of the incidence with a view to avoiding bias. Review of the DAPs between 1963 and 2010 from the 'yellow card' reporting scheme used in the UK showed one recorded case of type 1 hypersensitivity to tetracaine when single active constituent products were analysed. Multiple active constituent groups showed five additional cases with type 1 reactions. This scheme records all reported adverse events and includes immune-mediated reactions, anaphylactoid reactions, and also reactions to preservatives and additives within the product. A similar analysis reported by a French group of 210017 adverse reactions registered in the French Pharmacovigilance database over a 12 yr period between 1995 and 2006 identified 286 reports of suspected LA allergy. 18 Seven of these cases were selected on the basis of the history for further investigation and immediate allergic reactions were found in only three cases. Additionally, eight patients with immediate reactions were also identified from the GERAP (a French study group of peri-anaesthetic anaphylactoid reactions) database over a period of more than 20 yr (1985 -2006) . The true-positive cases described in individual case reports or identified by nation-wide surveillance schemes, considered in the context of the total number of patients receiving LA agents on a daily basis, support the safety profile of these agents and the low incidence of IgE-mediated reactions to them.
Adverse reactions to LA agents
LA agents are broadly divided into two main groups depending on their chemical structure: † amino-ester compounds: benzocaine, procaine, and butacaine; † amide compounds: lidocaine, bupivacaine, and prilocaine.
Theoretically, adverse reactions to LAs may occur as any one of the well-recognized Gell and Coombs hypersensitivity responses: namely, IgE-mediated, immune-complex disease, and delayed type hypersensitivity. Delayed hypersensitivity to LA as demonstrated by a positive patch test is well documented in the literature. 19 -21 Some reports also suggest an immune complex mediated aetiology to LA reactions where symptoms are associated with reduced complement levels. 22 23 In the early years of anaesthetic use, there were reports of deaths attributed directly to the use of the ester group of LAs, especially cocaine hydrochloride and procaine hydrochloride. 24 25 However, it is not clear if these represent pharmacological reactions or true allergy. Adverse reactions to ester compounds, especially contact dermatitis, are more commonly reported in the literature; however, there have also been sporadic reports of IgEmediated reaction to ester agents. 26 27 Amino-ester compounds are derivatives of para-amino benzoic acid (PABA), a common additive in lotions, cosmetics, and sunscreens. It is hypothesized that previous exposure to such PABAcontaining products can potentially sensitize a susceptible individual to amino-ester based LA agents. 28 Methylparaben, a preservative agent used in both ester and amide LA preparations, is also metabolized to PABA. Allergy to methylparaben may account for a significant proportion of the adverse reactions to LA. 29 It has therefore been recommended that patients be also evaluated for paraben allergy during investigation. Amide compounds are increasingly preferred in clinical practice as reactions to these agents are considered to be less common than the amino-ester group. There have, however, been reports of patients with true allergy to amides and documented cross-reactivity within the amide group. 30 -32 This has also been described in earlier studies of patients with contact dermatitis and delayed hypersensitivity based on patch test results. 28 33 Investigation of suspected LA allergy
Allergic reactions to LA agents have been postulated to be mediated via a hapten/hapten-carrier protein complex. 34 Investigations to find specific IgE to LA agents are still experimental. 35 This makes it difficult to have a reliable serum test to identify patients with sensitivity to LAs. Although serial measurements of serum mast cell tryptase concentrations immediately after a suspected reaction to the anaesthetic agent are recommended in the recently published guidelines by the BSACI, 7 tryptase levels are often lacking in the published literature on LA allergy. Evaluation of patients with a history of LA allergy has thus relied on careful and detailed history followed by direct SPTs using the suspect agent itself. 8 9 Schatz 9 has described protocols for both skin testing and subcutaneous incremental challenge in detail in 1984. On review of the literature, it has been interesting to note that there is a significant variability among clinicians with the protocols used for investigations. Most investigators have used a combination of skin tests and challenges to confirm diagnosis and find alternative agents, and protocols have often been tailored to suit individual clinical situations. The majority of authors have used or recommended vasoconstrictor-free preparations with or without preservatives, 8 -10 12 13 16 36 although a few have preferred to use preparations that contain these reagents on the basis that these are the products that are being used clinically in their local practice with or without preservatives. 15 37 Skin prick tests SPTs have been used as the initial investigation in the assessment of patients with suspected LA allergy. The number of agents to which the patients were tested, depended upon the available history. It is not uncommon for a patient to be tested to a range of LA from both amide and ester groups, including the suspect agent. SPTs are relatively easy and safe to perform, and in conjunction with the clinical history often helps to determine the most suitable LA for subsequent challenge testing. McClimon and colleagues, 16 in their review of 178 patients undergoing 227 skin tests, reported the negative predictive value of skin tests for LA allergy to be 97%.
Intra-dermal tests
Intra-dermal tests have been used either with or instead of SPTs. However, in addition to being a painful procedure for the patients, they are also associated with a high falsepositive rate (8-15%). 38 deShazo and Nelson noted a high degree of false-positive reactions (10/90 patients) while using the neat solution for intra-dermal testing as opposed to a 1:10 dilution (0/90 patients). 39 Four of these patients were then successfully challenged with the same agent without any reactions. The false-positive tests were presumed to be due to a primary irritant effect. Similarly, Incaudo and colleagues 40 also reported five positive reactions after intra-dermal testing, three of these patients were challenged with the same agent and had no reactions. Analysis of the published data within our review also showed a higher positive rate with intra-dermal testing (37/2648-1.4%) when compared with positive reactions as determined by challenge tests (19/2560-0.74%). The combination of a painful procedure with a high false-positive rate argues against the routine use of this test in the investigation of patients with suspected LA allergy.
Subcutaneous challenge tests
Subcutaneous challenges are considered to be the gold standard for confirmation of true IgE-mediated allergy to LA. However, challenge tests or drug provocation tests as a part of allergy investigations are generally controversial, especially if the suspect agent is being used for the test. One of the main arguments against drug provocation tests is the ethical issue of exposing a well patient to a dose of the suspect agent when they are otherwise normal (at the time of testing). Drug provocation tests should therefore be performed ideally in a hospital setting with easy access to emergency management, if required. This results in a substantial increase in the overall cost of investigation, which has also been the subject of discussion. Despite this, it is often essential to subject patients with suspected LA allergy to challenge testing in order to provide a safe alternative agent for future use. Protocols for challenge tests have been described in detail in earlier papers. 9 40 These have been subsequently modified by investigators to suit individual needs. 38 41 Provocative challenge testing as described by Chandler and colleagues 38 has its role in certain clinical situations, particularly in pregnant women presenting late to the obstetrician with a history of allergy to LAs, as used by other groups. 42 -44 It provides a useful method to identify a safe alternative for the individual patient. In the absence of a history clearly suggestive of type I allergy, direct re-challenge may be considered a safe and cheap alternative as opposed to embarking on lengthy and time-consuming investigations. 45 Subcutaneous challenges, however, are not without potential risk and it is recommended that the clinician estimates the risk -benefits for each individual case before initiating the challenge. It has been shown in previous studies that shorter challenge protocols can be safely used for the investigation of LA allergy. 38 41 It is possible that selected patients with a history of a reaction to LA and negative SPTs may safely be tested with an alternative LA using a Allergy to local anaesthetics much shorter protocol or even just a single-dose subcutaneous challenge. This is only possible with LA agents because it has been repeatedly shown by several investigators that true IgE-mediated reactions to LA are very rare. This approach may help to considerably shorten the evaluation time and also provide a safe alternative for future use.
Cross-reactivity between LAs
The primary objective of the assessment of suspected LA allergy in the drug allergy clinic is to identify an agent that can be safely used in the future. It is therefore important to consider the possibility of cross-reactivity between different agents. Amide compounds are increasingly preferred in clinical practice as reactions to these agents are considered to be less common than the amino-ester group. There are reports of patients with true allergy to amides and documented cross-reactivity within the amide group. 18 30 -32 35 The importance of considering crossreactivity and skin testing with several LA in order to identify a safe one has recently been highlighted by Fuzier and colleagues. 18 Cross-reactivity between the amide and ester groups has only been reported rarely, and when it has been reported may be attributed to paraben allergy in preservative containing amide preparations or co-sensitization. 13 43 46 Implications for UK practice
The BSACI guidelines on the investigation and management of drug allergy clearly stipulate that all suspected cases must be referred to specialist allergy clinics for further investigation. 7 In the light of this review reiterating the rarity of IgEmediated allergy to LA and given the current pressures experienced by the allergy services within the UK, we propose that only carefully selected patients with a good clinical history are referred for further investigation to the allergy services. Previously published algorithms are helpful in this regard. 9 13
Conclusion
This review of currently available data on adverse reactions to LA has reiterated the overall safety of these agents in clinical practice. Adverse reactions to LA are more often than not secondary to other causes rather than true IgE-mediated allergy. The investigation of patients with suspected allergy to LA should begin with a detailed history which should then determine whether skin testing and challenge is warranted. The evidence from this review shows that incremental challenge in patients with negative skin tests invariably demonstrates that the patient is tolerant of the relevant LA. In the light of these data, we therefore propose a single subcutaneous injection of the particular LA after negative skin tests is likely to be an adequate substitute for incremental challenge in this group of patients. For those patients with positive skin tests (skin prick, intra-dermal, or both), we suggest that skin testing and challenge with an unrelated LA be used to predict future safety.
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